{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-113949","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.763638+00:00","generated_at":"2026-05-15T09:54:10.395250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed","bullets":["Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).","Cash, equivalents and securities $514M; expected to fund operations into H2 2028.","4D-150 4FRONT-1 Phase 3 wet AMD enrollment completed; topline data expected H1 2027.","Otsuka partnership for 4D-150 in Asia-Pacific provided $85M upfront; up to $336M milestones plus royalties.","Leadership additions: new CFO Kristian Humer, CMO Julie Clark, CTO Katy Barglow, Board member Glenn Sblendorio."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-113949","json":"https://secwatch.observer/filing/0001193125-26-113949.json","markdown":"https://secwatch.observer/filing/0001193125-26-113949.md","text":"https://secwatch.observer/filing/0001193125-26-113949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/0001193125-26-113949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-20260318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:54:10.395250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}